SCHEMBL25301130

SCHEMBL25301130

CCOC(=O)c1cc2ccc(N3CC(C)(O)C3)cc2s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 2/20 0.42
MAPT P10636 6/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 4/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
CASP3 P42574 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
NR1H4 Q96RI1 1/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30492853 1.00 PTPN2 (0.42) PTPN2MAPTGAAKDM4ETDP1
SCHEMBL25811795 0.91 PTPN2 (0.40) PTPN2MAPTGAAKDM4ETDP1
SCHEMBL31025974 0.91 PTPN2 (0.40) PTPN2MAPTGAAKDM4ETDP1
SCHEMBL25296886 0.91 PTPN2 (0.40) PTPN2MAPTGAAKDM4ETDP1
SCHEMBL31025994 0.88 CHRNA7 (0.43) PTPN2MAPTGAAKDM4ETDP1
SCHEMBL25298855 0.88 CHRNA7 (0.43) PTPN2MAPTGAAKDM4ETDP1
SCHEMBL25810428 0.85 CHRNA7 (0.43) PTPN2MAPTGAAKDM4ETDP1
SCHEMBL30492874 0.85 CHRNA7 (0.43) PTPN2MAPTGAAKDM4ETDP1
SCHEMBL25809773 0.83 HRH4 (0.43) PTPN2MAPTGAAKDM4ETDP1
SCHEMBL30492821 0.83 CHRNA7 (0.53) PTPN2MAPTGAAKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074902-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) 2025-03-06 US disclosed
EP-4458824-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR Shanghai Jingxin Biomedical Co., Ltd. (CN) 2024-11-06 EP disclosed
CN-118488951-A Fused bicyclic heteroaryl amide compounds as inhibitors of protein aggregation 上海京新生物医药有限公司 2024-08-13 CN disclosed
WO-2023125376-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR 上海京新生物医药有限公司 2023-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074902-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR HTT, PARK7, FUS PTPN2 4737/4885MAPT 9/4885GAA 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.